KO enters the week before October earnings with an unusual wrinkle: the stock is up on the month, short sellers have turned mildly more active, and yet options traders have abruptly swung toward the most defensive posture of the past several months.
The options signal is the standout this week. The put/call ratio jumped to 0.96 on Tuesday — more than three standard deviations above its 20-day mean of 0.81, a z-score of 3.1 that marks it as one of the most extreme defensive readings in the past year. The context matters: the PCR had been running in a tight band between 0.76 and 0.89 for the better part of six weeks. Tuesday's spike, a single-day move to 0.96, represents a sharp break from that baseline. It is not yet at the 52-week high of 1.16, so there is room for hedging demand to intensify further. But the shift is sudden enough to flag — options traders are paying more for downside protection on a stock that has otherwise been remarkably calm.
Short interest tells a more ambiguous story this week than last. The previous two notes documented an unbroken retreat in KO's short book throughout the summer, from an April peak above 1.44% of free float to a low of 0.88% as of September 11. That retreat has now paused and reversed slightly. Short interest ticked back up to 0.94% of free float by September 15, adding roughly 2.4 million shares over four sessions. The one-week change is +3.4%. It is a small absolute level — not remotely crowded — but the directional shift breaks the trend that defined the prior five months. What has not changed: the borrow market remains fully open. Availability is at the capped maximum, with over 2.5 billion shares in the lending pool against roughly 40 million on loan. Cost to borrow is 0.41%, up 6% on the week but still negligible in absolute terms. Nothing in the lending market signals stress.
The Street remains broadly constructive, though the most recent cluster of analyst moves is now approximately seven weeks old. Following the July 28 Q2 print — which sent the stock up nearly 6% in a single session — JP Morgan, Wells Fargo, RBC, Jefferies, Barclays, and others all raised price targets, the bulk landing in the $93–$98 range against a consensus mean near $94.70. At $88.71, that implies roughly 7% upside to the average target. The valuation picture is not cheap: the trailing P/E is running near 25.8x and EV/EBITDA at 23.2x, both drifting modestly higher over the past month. The ORTEX factor scores assign a 95th-percentile dividend rank and a 76th-percentile short score — reflecting how lightly shorted the stock is relative to history — but the forward earnings growth score sits at the 20th percentile, a persistent drag that the bull case tries to offset with margin expansion and brand breadth.
Institutional ownership reinforces the patient-money profile. Berkshire Hathaway holds 9.3% of shares and has not moved its position. BlackRock added 5.3 million shares in its most recently reported period. Geode added 13 million. The picture is one of index and long-only managers slowly adding, not rotating out. Insider activity from late August was largely mechanics — Bruno Pietracci and EVP Nancy Quan both ran option exercises paired with same-day open-market sales, the standard compensation playbook rather than a discretionary signal. The 90-day net insider position across all trades is -1.7 million shares at a net value of -$149 million, but the bulk of that reflects those exercise-and-sell sequences rather than conviction selling.
The July earnings reaction is the most relevant recent reference point. KO rose 6% the day the Q2 numbers landed, an unusually large one-day move for a stock of this size and defensive character. The Q3 report is scheduled for October 20. With the short base ticking higher and options hedging picking up in the same week, the data is worth watching for whether the defensive shift in positioning deepens or proves to be a single-session artifact before the print.
See the live data behind this article on ORTEX.
Open KO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
